Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products

Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations... BACKGROUND: Patients with hematologic malignancies often require blood products, and parvovirus B19 is known to be transmitted by this route. Primary infection with parvovirus B19 shows a wide variety of disease manifestation. In immunocompromised patients, symptoms are severe and viral clearance is delayed or missing. STUDY DESIGN AND METHODS: A total of 2123 blood products given to all patients of a hematologic ward over a period of 6 months were retrospectively examined for the presence of parvovirus B19 DNA by an in‐house real‐time polymerase chain reaction (PCR; TaqMan). Patients who had received B19 DNA–positive blood products were further investigated serologically and by PCR for the presence of parvovirus B19 antibodies and DNA. RESULTS: Twenty‐one (1%) of 2123 blood products tested positive for the presence of B19 DNA (2% of pooled products, 0.7% of single‐donor products, and 17.6% of allogeneic peripheral blood progenitor cells), the median viral load was 700 genome equivalents per mL. During the study period, 114 patients were treated on the ward, and 14 (12%) of them received B19 DNA–positive blood components. None of them developed symptoms of an acute B19 infection, although one had a short low‐level viremia. CONCLUSIONS: Although B19 DNA was detected in 1 percent of blood products given to hematologic patients, the exposure of 12 percent of patients did not result in symptomatic infections. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Transfusion Wiley

Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products

Loading next page...
 
/lp/wiley/exposure-of-hematologic-patients-to-parvovirus-b19-as-a-contaminant-of-2i7gNcdvgK

References (42)

Publisher
Wiley
Copyright
Copyright © 2005 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0041-1132
eISSN
1537-2995
DOI
10.1111/j.1537-2995.2005.00610.x
pmid
16271109
Publisher site
See Article on Publisher Site

Abstract

BACKGROUND: Patients with hematologic malignancies often require blood products, and parvovirus B19 is known to be transmitted by this route. Primary infection with parvovirus B19 shows a wide variety of disease manifestation. In immunocompromised patients, symptoms are severe and viral clearance is delayed or missing. STUDY DESIGN AND METHODS: A total of 2123 blood products given to all patients of a hematologic ward over a period of 6 months were retrospectively examined for the presence of parvovirus B19 DNA by an in‐house real‐time polymerase chain reaction (PCR; TaqMan). Patients who had received B19 DNA–positive blood products were further investigated serologically and by PCR for the presence of parvovirus B19 antibodies and DNA. RESULTS: Twenty‐one (1%) of 2123 blood products tested positive for the presence of B19 DNA (2% of pooled products, 0.7% of single‐donor products, and 17.6% of allogeneic peripheral blood progenitor cells), the median viral load was 700 genome equivalents per mL. During the study period, 114 patients were treated on the ward, and 14 (12%) of them received B19 DNA–positive blood components. None of them developed symptoms of an acute B19 infection, although one had a short low‐level viremia. CONCLUSIONS: Although B19 DNA was detected in 1 percent of blood products given to hematologic patients, the exposure of 12 percent of patients did not result in symptomatic infections.

Journal

TransfusionWiley

Published: Nov 1, 2005

There are no references for this article.